Q2 FY2026 · ended Jun 30, 2026 · Revenue $22.83M, +17.1% YoY · Filed Aug 11, 2026
Neuropace, Inc. (NPCE) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $22.8 million and a net loss of $6.2 million. Free cash flow was -$4.0 million. As of Jun 30, 2026 it held $51.7 million in cash and investments and $69.9 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NPCE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1528287
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $22.8M | $22.1M | $26.6M | $27.4M | $19.5M |
| Operating income | -$5.1M | -$5.6M | -$1.8M | -$2.6M | -$8.2M |
| Net income | -$6.2M | -$6.7M | -$2.7M | -$3.5M | -$8.7M |
| Diluted EPS | -$0.18 | -$0.20 | -$0.08 | -$0.11 | -$0.26 |
| Operating cash flow | -$3.9M | -$5.9M | $506,000 | -$1.9M | -$2.1M |
| Free cash flow | -$4.0M | -$6.0M | $409,000 | -$2.0M | -$2.3M |
| Total assets | $97.0M | $98.9M | $105.6M | $107.3M | $106.1M |
| Total liabilities | $85.1M | $84.4M | $86.5M | $88.7M | $86.7M |
| Stockholders' equity | $11.9M | $14.5M | $19.0M | $18.5M | $19.4M |
| Cash and investments | $51.7M | $54.0M | $61.1M | $60.0M | $62.1M |
| Total debt | $69.9M | $70.5M | $70.8M | $71.2M | $71.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | Mar 31, 2026 |
All 353 Neuropace, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.